Search Result

Results for "

human factor Xa

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor Xa (26) Biochemical Assay Reagents (1) Drug Metabolite (2) Endogenous Metabolite (2) Isotope-Labeled Compounds (1) Kallikrein (2) Proteasome (2) Reference Standards (5) Ser/Thr Protease (5) Thrombin (8)
By Research Areas:	Cancer (9) Cardiovascular Disease (26) Inflammation/Immunology (4) Metabolic Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: Factor Xa

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50667

Apixaban Maximum Cited Publications 13 Publications Verification BMS-562247-01	Factor Xa	Cardiovascular Disease Cancer
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-10264

Edoxaban 5+ Cited Publications DU-176	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-B0385

Gabexate mesylate 4 Publications Verification FOY	Proteasome Factor Xa	Inflammation/Immunology
Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with K_is of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with K_is of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .

HY-10264B

Edoxaban tosylate monohydrate 5+ Cited Publications DU-176b monohydrate	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-10264A

Edoxaban tosylate 5+ Cited Publications DU-176b	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .

HY-119124

Edoxaban M4 D21-2393	Factor Xa	Cardiovascular Disease Inflammation/Immunology
Edoxaban M4 (D21-2393) is an orally active and selective Factor Xa inhibitor with a human Factor Xa IC₅₀ of 1.8 nM. Edoxaban M4 exhibits anticoagulant activity via Factor Xa inhibition. Edoxaban M4 can be used for the research of non-valvular atrial fibrillation, venous thromboembolisms, pulmonary embolism .

HY-P990060

Denecimig Mim8	Factor Xa	Cardiovascular Disease
Denecimig (Mim8) is a factor VIII-mimetic bispecific antibody with micromolar human binding affinity for Factor X and Factor IXa. Denecimig binds Factor X and Factor IXa, localizes both to the phospholipid surface, enhances the Factor IXa-mediated activation of Factor X to Factor Xa, and stimulates the proteolytic activity of Factor IXa via its monovalent anti-Factor IXa arm. Denecimig is applicable to research related to hemophilia A .

HY-50667S

Apixaban-13C,d3 BMS-562247-01-¹³C,d₃	Factor Xa	Cardiovascular Disease
Apixaban- ¹³C,d₃ (BMS-562247-01- ¹³C,d₃) is a deuterium and ¹³C labeled Apixaban (HY-50667). Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-100655

O-Desmethyl apixaban	Drug Metabolite	Cardiovascular Disease
O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-50667R

Apixaban (Standard) BMS-562247-01 (Standard)	Reference Standards Factor Xa	Cardiovascular Disease Cancer
Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-50667S1

Apixaban-d3 BMS-562247-01-d₃	Isotope-Labeled Compounds Factor Xa	Others
Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_is of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-10264R

Edoxaban (Standard) DU-176 (Standard)	Reference Standards Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-76971

Dechloro Rivaroxaban	Factor Xa	Cardiovascular Disease
Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a K_i of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC₅₀s of 2.1 nM and 92 nM, respectively .

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-10722

DX-9065a	Factor Xa	Cardiovascular Disease
DX-9065a is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a K_i of 41 nM for human FXa. DX-9065a has low activity against other serine proteases. DX-9065a has strong anticoagulant actions .

HY-172316

BAY 3389934	Factor Xa	Cardiovascular Disease
BAY 3389934 is a selective dual inhibitor of factor IIa and factor Xa, with an IC₅₀ of 4.9 nM for factor IIa and an IC₅₀ of 0.66 nM for factor Xa. BAY 3389934 directly inhibits the activities of factor IIa and factor Xa and regulates the common coagulation pathway. BAY 3389934 exhibits anticoagulant and organ-protective effects. BAY 3389934 can be used in the research of sepsis and coagulopathy .

HY-118803

AS1468240	Factor Xa	Others
AS1468240 is an orally active inhibitor for *anticoagulant factor* Xa (fXa)*, that inhibits human* fXa with IC₅₀ of 8.7 nM. AS1468240 prolongs the coagulation time in mice .

HY-100655R

O-Desmethyl apixaban (Standard)	Reference Standards Drug Metabolite	Cardiovascular Disease
O-Desmethyl apixaban (Standard) is the analytical standard of O-Desmethyl apixaban. This product is intended for research and analytical applications. O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-10722A

DX-9065a free base	Factor Xa	Cardiovascular Disease
DX-9065a free base is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a K_i of 41 nM for human FXa. DX-9065a free base has low activity against other serine proteases. DX-9065a free base has strong anticoagulant actions .

HY-11090A

DPC423	Factor Xa Kallikrein Thrombin Ser/Thr Protease	Cardiovascular Disease
DPC423 is a selective and orally active factor Xa inhibitor with a K_is of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits K_is of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 can be used for the study of anticoagulation of arterial thrombosis .

HY-10264C

Edoxaban hydrochloride DU-176 hydrochloride	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .

HY-11090

DPC423 free base	Factor Xa Kallikrein Thrombin Ser/Thr Protease	Cardiovascular Disease
DPC423 free base is a selective and orally active factor Xa inhibitor with a K_is of 0.15 (human) and 0.3 (rabbit) nM. DPC423 free base exhibits K_is of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 free base blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 free base can be used for the study of anticoagulation of arterial thrombosis .

HY-B0385R

Gabexate mesylate (Standard) FOY (Standard)	Reference Standards Proteasome Factor Xa	Inflammation/Immunology
Gabexate (mesylate) (Standard) is the analytical standard of Gabexate (mesylate). This product is intended for research and analytical applications. Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .

HY-10281

YM-60828 methanesulfonate	Factor Xa	Cardiovascular Disease
YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-10780

JTV-803 mesylate	Endogenous Metabolite	Cardiovascular Disease
JTV-803 mesylate is a human factor Xa inhibitor with oral anticoagulant activity. JTV-803 exhibits competitive inhibition of human factor Xa, with a K_i value of 0.019μM and IC₅₀Value is 0.081μM. JTV-803 is 100 times more selective at inhibiting human factor Xa than its comparator. JTV-803 is an effective oral anticoagulant for the prevention of thrombosis .

HY-182420

DJT06001	Factor Xa	Cardiovascular Disease
DJT06001 is an orally active, highly selective Factor Xa inhibitor. DJT06001 shows inhibition with K_i of 0.99 nM, IC₅₀ of 2.53 nM in prothrombinase complex and 3.33 nM in human plasma. DJT06001 dose-dependently prolongs PT and APTT, inhibits thrombus formation in vivo. DJT06001 can be used for the research of thromboembolic diseases .

HY-10264BR

Edoxaban tosylate monohydrate (Standard) DU-176b monohydrate (Standard)	Reference Standards Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban tosylate monohydrate (Standard) is the analytical standard of Edoxaban tosylate monohydrate (HY-10264B). This product is intended for research and analytical applications. Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-165180

Lyso-sulfatide (bovine) sodium Psychosine 3′-O-sulfate sodium; Psychosine 3′-sulfate sodium	Biochemical Assay Reagents Factor Xa	Metabolic Disease
Lyso-sulfatide (bovine) sodium is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) sodium binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) sodium serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions .

HY-W794573

APC-6860 (hydrochloride)	Ser/Thr Protease	Cancer
APC-6860 hydrochloride is a competitive, selective arylamidine Serine protease inhibitor, with a K_i of 0.44 μM for trypsin, 0.10 μM for h-uPA, and 0.082 μM for mouse uPA. APC-6860 hydrochloride inhibits urokinase-activated plasminogen-mediated degradation of Fibronectin in cancer cells. APC-6860 hydrochloride is applicable to research related to breast cancer and prostate cancer .

HY-135541

Darexaban maleate YM150 maleate	Endogenous Metabolite	Cardiovascular Disease
Darexaban maleate (YM150 maleate) is a direct factor Xa inhibitor with activity in preventing venous thromboembolism. The major metabolite of Darexaban maleate in humans is Darexaban glucitol, which acts pharmacologically. The glucitolation reaction of Darexaban maleate is mainly catalyzed by UGT1A9 and UGT1A10 in the human liver and intestine. The K(m) value of Darexaban maleate glucitolation in the liver is greater than 250 μM, while in the intestine it exhibits substrate inhibition kinetics with a K(m) value of 27.3 μM. The unbound K(m) value of Darexaban maleate is significantly reduced by the influence of fatty acid-free bovine serum albumin in both HLM and UGT1A9 .

HY-182406

CU-2010	Ser/Thr Protease	Cardiovascular Disease
CU-2010 is a Serine protease inhibitor. In canine models, CU-2010 reduces blood loss after cardiac surgery in a dose-dependent manner and improves post-ischemic recovery .

HY-10279

YM-60828 hydrochloride	Factor Xa	Cardiovascular Disease
YM-60828 hydrochloride is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 hydrochloride inhibits thrombus formation and platelet aggregation. YM-60828 hydrochloride can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-185463

β-Tryptase-IN-1	Ser/Thr Protease	Inflammation/Immunology
β-Tryptase-IN-1 is a selective β-tryptase inhibitor with a K_i of 10 nM. β-Tryptase-IN-1 binds to the inducible S4 ⁺ pocket unique to β-tryptase. β-Tryptase-IN-1 can be used for the researches of asthma and chronic obstructive pulmonary disease (COPD) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990060

Denecimig Mim8	Factor Xa	Cardiovascular Disease
Denecimig (Mim8) is a factor VIII-mimetic bispecific antibody with micromolar human binding affinity for Factor X and Factor IXa. Denecimig binds Factor X and Factor IXa, localizes both to the phospholipid surface, enhances the Factor IXa-mediated activation of Factor X to Factor Xa, and stimulates the proteolytic activity of Factor IXa via its monovalent anti-Factor IXa arm. Denecimig is applicable to research related to hemophilia A .

Cat. No.	Product Name	Chemical Structure

HY-50667S

Apixaban-13C,d3
Apixaban- ¹³C,d₃ (BMS-562247-01- ¹³C,d₃) is a deuterium and ¹³C labeled Apixaban (HY-50667). Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-50667S1

Apixaban-d3
Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_is of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: